Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• ISS and Glass Lewis both recommended voting for all management director nominees and against the dissident slate, citing improved performance and proactive board actions following the 5x30 strategy launch.

• The dissident group, DOMA Perpetual, was criticized for lacking a compelling case for change and for nominating individuals without public board or strategic review experience.

• Forward-looking statements highlight ongoing execution of the 5x30 plan, product development, and risk factors affecting future results.

Voting matters and shareholder proposals

• Stockholders are urged to vote for Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans as directors on the BLUE proxy card.

• Voting against all three DOMA Perpetual nominees is recommended by both ISS and Glass Lewis.

• Instructions provided for proxy voting by internet, phone, or mail, and shareholders are advised to disregard any white proxy card from DOMA.

Board of directors and corporate governance

• Board separated CEO and chair roles in January 2024, appointing Frank Lee as CEO.

• Seven of ten directors were appointed or proposed since October 2023, bringing relevant experience for the 5x30 plan.

• Board credited for proactive refreshment and strategic oversight, positioning the company for accelerated execution.